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Purpose: Osteoprotegerin (OPG), a potent inhibitor of
osteoclastic bone resorption, has a variety of biological
functions that include anti-inflammatory effects. Adipocytes
and osteoblasts share a common origin, and the formation of
new blood vessels often precedes adipogenesis in developing
adipose tissue microvasculature. We examined whether OPG
is secreted from adipocytes, therefore contributing to the
prevention of neovascularization and protecting the vessels
from intimal inflammation and medial calcification. Materials
and Methods: The mRNA expression of OPG and receptor
activator of NF- B ligand (RANKL) was measured in κ
differentiated 3T3L1 adipocytes and adipose tissues. Results:
OPG mRNA expression increased with the differentiation of
3T3L1 adipocytes, while RANKL expression was not
significantly altered. OPG mRNA was expressed at higher
levels in white adipose tissue than in brown adipose tissue and
was most abundant in the epididymal portion. In differentiated
3T3L1 adipocytes, Rosiglitazone and insulin reduced the
OPG/RANKL expression ratio in a dose- and time- dependent
manner. In contrast, tumor necrosis factor- (TNF- ) increased α α
the expression of both OPG and RANKL in a time-dependent
manner. The OPG/RANKL ratio was at a maximum two hours
after TNF- treatment and then returned to control levels. α
Furthermore, OPG was abundantly secreted into the media
after transfection of OPG cDNA with Phi C31 integrase into
3T3L1 cells. Conclusion: Our results indicate that OPG mRNA
is expressed and regulated in the adipose tissue. Considering
the role of OPG in obesity-associated inflammatory changes
in adipose tissue and vessels, we speculate that OPG may have
both a protective function against inflammation and anti-
angiogenic effects on adipose tissue.
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INTRODUCTION
Osteoprotegerin (OPG), an anti-inflammatory
protein derived from osteoblasts, decreases bone
resorption by inhibiting the differentiation and
activation of osteoclasts.
1,2 The receptor activator
of NF- B ligand (RANKL) is highly expressed by κ
T-cells in lymphoid tissue and osteoblast and
stromal cells in bone, especially in areas under-
going active bone remodeling or inflammatory
osteolysis.
2 Since the discovery of RANKL, the
receptor activator of NF- B (RANK), and the OPG κ
system, much has been learned about the
developmental, homeostatic, and pathologic roles
that these molecules have in controlling cell
recruitment, differentiation, and apoptosis in
skeletal and immune biology.
2-4 Interest in the
RANKL/RANK/OPG system has been further
heightened by the discovery that it may mediate
important and complex linkages between the
vascular, skeletal, and immune systems.
5,6
Vascular calcification is triggered by active
processes involving inflammatory cytokines, other
signals, or by disordered calcium and phosphate
homeostasis.
7 Like most biological processes,
vascular calcification is subject to complex
positive or negative regulatory networks.
6,7 Recent
research on a newly discovered group of molecules
belonging to the tumor necrosis factor-related
family has suggested that RANK, RANKL, and
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OPG may have unexpected roles in vascular
biology and pathophysiology.
6 In OPG knockout
mice, two-thirds of the mice have unexpected late
medial calcification of the renal and aortic arteries,
which are sites of abundant endogenous OPG
expression in normal animals.
3,8 Calcified arteries
in OPG knockout mice also express RANKL and
RANK, but these proteins are undetectable in
normal murine arteries.
3,8 Systemic OPG delivery
in OPG knockout mice from mid-gestation through
adulthood prevented vascular calcification, whereas
transient OPG administration failed to reverse
arterial mineralization once it had occurred.
7,8 In
studies with rats, OPG administration prevented
calcification induced by warfarin or high doses of
vitamin D.
9 In humans, plasma OPG levels were
elevated in patients with type 2 diabetes, coronary
artery diseases, hypothyroidism, hypercholestero-
lemia, or abdominal obesity, as well as in aging
men.
10-14 These findings suggest that the RANKL/
RANK/OPG system may be involved in regulating
vascular calcification in humans.
Angiogenesis, the development of new blood
vessels from pre-existing endothelium, is a critical
process for many physiological and pathological
conditions including embryonic development,
organ regeneration, chronic inflammation, and
solid tumor growth.
15 Recently, Min et al. reported
that RANKL is involved in bone formation and
cartilage destruction in a rat adjuvant arthritis
model.
8 Nakashima et al. showed that RANKL
expression can be regulated in stromal cells by a
variety of cytokines generated by tumor-asso-
ciated macrophages.
16 Furthermore, another study
found that the inflammatory cytokines tumor
necrosis factor- (TNF- ) and interleukin-1 (IL-1 α α α
) elevate RANKL expression in human micro α -
vascular endothelial cells.
17 Together, these findings
suggest that RANKL plays a role in the formation
of microvessels at both tumor and inflammatory
sites.
In the search for novel anti-obesity drugs,
Rupnick et al. recently speculated that neovascul-
arization may be critical for adipose tissue
growth.
18 By using various mouse models of obesity
and the unique features of the microvasculature
within adipose tissue, this study showed that
systemic treatment with angiogenesis inhibitors
results in weight reduction and adipose tissue
loss. Since adipose tissue has enormous growth
potential, given an appropriate metabolic challenge,
it displays a high degree of plasticity with respect
to its vascularization. Interestingly, angiogenesis,
or the formation of new blood vessels from existing
vessels, often precedes adipogenesis in developing
adipose tissue microvasculature.
19 Therefore, we
hypothesized that RANKL and OPG might be
expressed in adipocytes and thus contribute to
adipogenesis and intimal inflammation and medial
calcification of blood vessels.
MATERIALS AND METHODS
Cell culture
3T3L1 cells were cultured in Dulbecco's modified
high-glucose Eagle's medium (DMEM 90%; 10%
(v/v) fetal calf serum (FCS)) (Gibco, Gaithersburg,
MD, USA) in a humidified incubator at 37 with
a 5% CO2 atmosphere. When cells reached
confluency the media was changed to DMEM
containing 10% FCS, 10 g/mL insulin, 1 μ M μ
dexamethasone, and 0.5 mM isobutylmethyl-
xanthine. Two days later, the isobutylmethyl-
xanthine and dexamethasone were removed and
the insulin was maintained in the media for 2
additional days. After four days, the media was
replaced with DMEM (without insulin supple-
mentation) plus 10% fetal bovine serum.
Thereafter, the cells were re-fed with the same
media every 2 days. The 3T3L1 cells were serum-
starved overnight in DMEM/0.5% (v/v) FCS and
transferred to Krebs-Ringer bicarbonate Hepes
buffer, pH 7.4, containing 1% (w/v) BSA and 5
mM glucose for 90 min prior to treatment.
Plasmid construction
A full-length mouse OPG cDNA was obtained
by RT-PCR amplification of total RNA that had
been isolated from MC3T3E1 cells. The cDNA was
subcloned into a pcDNA 3.0 vector. For long-term
expression of OPG, site-specific genomic integra-
tion of OPG cDNA was achieved by transfecting
OPG cDNA subcloned into the attB restriction site
of a pcDNA vector containing a Phi C31 integrase.
The pTA-attB plasmid and pCMV-integrase wereOsteoprotegerin in Adipose Tissue
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kindly donated by Professor Calos MP.
20
Transfections
3T3L1 cells were plated on 6-well plates at a
density of 1 × 10
5 cells/well the day before trans-
fection. A total of 1 g of each plasmid DNA was μ
mixed with lipofectamine reagent (Invitrogen) and
transfected into cells according to the manu-
facturer's protocol. At 48 h post-transfection, the
total cellular RNA was extracted from the cells.
Semiquantitative reverse transcription-polymerase
chain reaction
Total RNA from adipose tissue of Sprague-
Dawley rats (male, 5 - 6 wks) and 3T3L1 cells was
isolated using Tri-reagent (Invitrogen, Carlsbad,
CA, USA) and then treated with DNase I
(Promega). The isolated RNA was quantitated by
absorbance at 260 nm; the 260/280 ratio was 1.8
or higher. One g of total RNA was reverse μ
transcribed using 2 U of MMLV reverse tran-
scriptase (Promega), 0.5 g of random primer μ
(Promega), 0.25 mM dNTPs (Promega), and 10 U
RNAsin (Promega) in a total volume of 20 uL.
PCR amplification reactions contained 1 uL of
RT-PCR product, 0.2 mM dNTPs, and 1.5 U Taq
polymerase (Promega) in a final volume of 50 uL.
PCR amplification of mouse or rat OPG was
performed with 30 cycles of 94℃ for 30 sec, 60℃
(mouse) or 55℃ (rat) for 30 sec, and 72℃ for 1
min. PCR amplification of mouse or rat RANKL
was performed with 30 cycles of 94℃ for 30 sec,
56℃ (mouse) or 53℃ (rat) for 30 sec, and 72℃ for
1 min. Primers sequences were as follows: OPG
(rat): forward 5'-GTTCTTGCACAGCTTCACCA-
3' and reverse 5'-AAACAGCCCAGTGACCATTC-
3'; OPG (mouse): forward 5'-ATGCCGAGAGTGT
AGAGAGGAT-3' and reverse 5'-AAACAGCCCA
GTGGACCATTCCT-3'; RANKL (rat): forward 5'-
ACCAGCATCAAAATCCCAAG-3' and reverse 5'-
TTTGAAAGCCCCAAAGTACG-3'; RANKL (mouse):
forward 5'-ACCAGCATCAAAATCCCAAG-3' and
reverse 5'-TTTGAAAGCCCCAAAGTACG-3'; - β
actin (rat): forward 5'-AAGCAGGAGTATGACGA
GTCCG-3' and reverse 5'-GCCTTCATACATCTC
AAGTTGG-3'; -actin (mouse): forward 5'-TTCA β
ACACCCCAGCCATGT-3' and reverse 5'-TGTGG
TACGACCAGAGGCATAC-3'.
Treatment with TNF- , insulin, and Rosiglitazone α
To study the effects of TNF- on the expression α
of OPG and RANKL in adipocytes, 3T3L1 cells
were treated with TNF- (20 α ng/mL), insulin (10
g/mL), or Rosiglitazone (10 μ
-7 - 10
-5M) for 12 days
after the induction of differentiation.
Measurement of OPG by ELISA
The concentration of OPG in the culture
medium was determined using ELISA. Briefly,
96-well plates were coated with 2 g/mL mouse μ
monoclonal anti-human OPG (R&D Systems,
Quantikine
R). An OPG standard curve was gener-
ated using recombinant mouse OPG (R&D
Systems) at concentrations from 31.25 to 2000 to
pg/mL. Biotinylated anti-mouse OPG (R&D
Systems) at 200 ng/mL was used for the secondary
antibody, and OPG was detected with strepta-
vidin-horseradish peroxidase (R&D Systems) in
combination with 3,3', 5,5'-tetramethylbenzidine
(Sigma Chemical Co.). The reaction was stopped
after a 5 - 20 min incubation in the dark by the
addition of 50 L of 2 μ M H2SO4. The plate was
read at 450 nm on a Dynatech plate reader with
Revelation software.
Statistical analysis
Results are expressed as the mean value ± SE.
Student's t-test was used for statistical analysis.
Relationships with p values less than 0.05 were
considered statistically significant.
RESULTS
Expression of OPG and RANKL during adipo-
cyte differentiation
Expression of OPG mRNA increased with
3T3L1 adipocyte differentiation from 0 to 12 days
after treatment with a differentiation cocktail solu-
tion. In contrast, RANKL mRNA levels did not
change significantly (Fig. 1). Results are expressed
as the mean value of 5 different experiments.Juan-Ji An, et al.
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Differential expression of OPG and RANKL in
various adipose depots in the rat
In the rat, OPG mRNA was expressed at higher
levels in white adipose tissue than in brown
adipose tissue and most abundantly in epididy-
mal adipose tissue (Fig. 2).
Regulation of OPG/ RANKL expression of in the
presence of TNF-α
To study the effects of TNF- on the expression α
of OPG and RANKL in adipocytes, 3T3L1 cells
were treated with TNF- (20 α ng/mL) 12 days after
the induction of differentiation. After 6 hrs of
treatment with TNF- , both OPG and RANKL α
mRNA levels increased significantly in differen-
tiated 3T3L1 adipocytes. RANKL mRNA levels
increased more (2.5-fold) than OPG mRNA levels
(1.8-fold) when compared to their expression
levels in untreated 3T3L1 cells. The maximum
OPG/RANKL ratio occurred two hours after
treatment with TNF- and then returned to α
control levels (Fig. 3).
Regulation of OPG/ RANKL expression in the
presence of insulin
Exposure of 3T3L1 adipocytes to insulin (10 g/ μ
mL) decreased the expression of OPG mRNA (Fig.
4). Indeed, after 4 hrs of insulin treatment, OPG
mRNA levels were suppressed by up to 70 - 80%.
Expression of RANKL mRNA was higher after 6
hrs of insulin treatment.
Fig. 1. Expression of OPG/RANKL during adipocyte
differentiation. Expression of OPG mRNA increased with
the level of 3T3L1 preadipocyte differentiation, while
mRNA levels of RANKL did not significantly change.
OPG, osteoprotegerin; RANKL, receptor activator of NF-κ
B ligand. *p < 0.05.
Fig. 2. Differential expression of OPG/RANKL in various
adipose depots in Sprague-Dawley rats. The pattern of
mRNA expression of OPG/RANKL in subcutaneous
adipose tissue was similar in mice, rats, and humans.
Levels of OPG mRNA were higher in white adipose tissue
than in brown adipose tissue, with the most abundant
levels occurring in epididymal adipose tissue. WAT, white
adipose tissue; BAT, brown adipose tissue; eWAT, epi-
didymal white adipose tissue; pWAT, periomental white
adipose tissue; sqWAT, subcutaneous white adipose
tissue.
Fig. 3. Regulation of OPG and RANKL expression in the
presence of TNF- . TNF- enhanced the expression of α α
both OPG and RANKL mRNA in 3T3L1 preadipocytes.
The OPG/RANKL ratio after TNF- treatment was at a α
maximum two hours after treatment with TNF- and then α
returned to control levels. *p < 0.05.Osteoprotegerin in Adipose Tissue
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Regulation of OPG/ RANKL expression in the
presence of Rosiglitazone
Exposure of 3T3L1 adipocytes to Rosiglitazone
decreased the expression of OPG mRNA in a
dose-dependent manner (Fig. 5). OPG was sup-
pressed more strongly than RANKL.
Secretion of OPG into the media after transfection of
OPG cDNA
After the OPG cDNA was transfected into
3T3L1 cells, the cellular expression of OPG was
evident. In differentiated 3T3L1 cells, however,
OPG that had been secreted into culture media
Fig. 6. OPG secretion after transfection of OPG cDNA into
3T3L1 preadipocytes. (A) Differentiation of 3T3L1 prea-
dipocytes: a) 3T3L1 cells were first transfected with
pcDNA 3.0-attB-OPG-IRES-puromycin DNA and pCMV
integrase DNA for genomic integration. Then, the adi-
pocytes were differentiated with puromycin selection for
14 days. b) 3T3L1 cells were first differentiated into
adipocytes for 12 days and then transfected with pcDNA
3.0-attB-OPG-IRES-puromycin DNA only for acute trans-
fection. The culture media was then collected and assayed
3 days after transfection. (B) Levels of OPG secretion as
measured with an ELISA kit. Mock represents results
from media obtained from 3T3L1 cells transfected with
vector DNA. BD, before differentiation; AD, after differ-
entiation; TBD, transfection before differentiation, which
was from media obtained from 3T3L1 cells transfected
with both pcDNA 3.0-attB-OPG-IRES-puromycin DNA
and pCMV integrase DNA prior to differentiation into
adipocytes; and TAD, transfection after differentiation,
which was from media obtained from 3T3L1 cells differ-
entiated into adipocytes first for 12 days and transfected
with pcDNA 3.0-attB-OPG-IRES-puromycin DNA. Values
are mean ± SE from 5 observations.
Fig. 4. Regulation of OPG/RANKL expression in the
presence of insulin. Insulin (10 g/mL) decreased the μ
expression of OPG mRNA in 3T3L1 preadipocytes. *p <
0.01.
Fig. 5. Regulation of OPG/RANKL expression in the
presence of Rosiglitazone. Rosiglitazone decreased the
expression of OPG mRNA in 3T3L1 preadipocytes in a
dose-dependent manner. *p < 0.05, **p < 0.01.
A
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was barely detectable by ELISA. In contrast,
ample amounts of OPG were detectable in the
media with 3T3L1 cells that had been transiently
transfected with OPG cDNA (Fig. 6). One possible
explanation for this result may be that OPG
secretion in differentiated 3T3L1 cells might be
present at levels insufficient for detection by
ELISA.
DISCUSSION
In the present study, we found that both OPG
and RANKL mRNAs were expressed in adipo-
cytes and that both of these proteins were differ-
entially expressed in various adipose deposits.
Furthermore, both OPG and RANKL were regu-
lated by TNF- , insulin, and Rosiglitazone. α
The phenotype of osteoporosis and vascular
calcification in OPG knockout mice has revitalized
the hypothesis that metabolic bone diseases and
vascular diseases, such as arterial calcification,
share common pathways.
3 Price et al. reported
that OPG administration prevents calcification in-
duced by warfarin or high doses of vitamin D in
rats,
9 but the effects of OPG in humans are dif-
ferent from those in rodents. A cohort study of
postmenopausal women, aged at least 65 years,
revealed that OPG serum levels are 30% higher in
women with diabetes mellitus than those without,
and are positively correlated with overall cardio-
vascular mortality.
10 Similarly, a study on Japanese
subjects found that serum OPG levels correlated
positively with the severity of coronary arterial
disease.
12 However, based on the phenotype of
OPG-deficient mice, elevated serum OPG levels in
humans should be an insufficient counter-regu-
latory mechanism to prevent further bone loss
and vascular lesions.
7 RANKL and OPG are
produced by extraosseous tissues and various
skeletal tissues, therefore, serum levels for OPG or
RANKL might not reflect their actual expression
in specific tissues. Thus, the regulation and spe-
cific roles of OPG and RANKL in extraosseous
tissues, including vessels, have not yet been fully
determined.
Disturbance of the OPG/RANKL ratio is con-
sidered a pivotal cause of a number of osteolytic
disorders, including glucocorticoid-induced oste-
oporosis, rheumatoid arthritis, hyperparathyroi-
dism, myeloma bone disease, and osteolytic bone
metastases.
21 Here, we demonstrated the expres-
sion of both OPG and RANKL in adipocytes (Fig.
1). Specifically, expression of OPG mRNA in-
creased with the differentiation of 3T3L1 preadi-
pocytes, while RANKL mRNA expression was not
significantly altered. Adipose tissue is not simply
an energy storage depot; adipose tissue also func-
tions as an active endocrine organ through its
secretion of various cytokines.
22 In our study, we
observed the differential expression of OPG and
RANKL in various adipose deposits in a Sprague-
Dawley rat (Fig. 2). The pattern of OPG/RANKL
mRNA expression in subcutaneous adipose tissue
was similar in mice, rats, and humans (data not
shown). OPG mRNA was expressed at higher
levels in white adipose tissue than in brown
adipose tissue and was most abundant in epididy-
mal adipose tissue. Most fat in the human body
is white adipose tissue. Recently, secretion of
inflammatory cytokines and angiogenic factors by
white adipose tissue has been stressed. Therefore,
increases in the OPG/RANKL ratio in white
adipose tissue have an important significance and
are more indispensable for obese patients.
OPG was exclusively secreted 12 hours after
transient transfection with OPG cDNA in un-
differentiated and differentiated 3T3L1 cells (Fig.
6). Because adipose tissue comprises considerable
portions of the body and the amount of plasma
OPG varies in different metabolic conditions, our
results may provide a reasonable explanation for
the previously generated clinical data.
10-13
Many cytokines and systemic factors are known
to regulate the expression of OPG and RANKL in
osteoblasts.
23 TNF- and interleukin-1 stimulate α β
OPG mRNA expression and secretion by osteo-
blast-like MG-63 cells.
24 We also observed that
TNF- significantly increased both OPG and α
RANKL mRNA levels in differentiated 3T3L1
adipocytes (Fig. 3). In obese subjects, adipocytes
secrete low levels of TNF- , which can stimulate α
preadipocytes to produce the monocyte chemoat-
tractant protein-1, thereby recruiting macro-
phages.
25 Recently, Min et al. reported that
RANKL is an angiogenic factor in bone and
cartilage.
8 Therefore, elevation of RANKL by TNF-
could stimulate angiogenesis in adipose tissue. αOsteoprotegerin in Adipose Tissue
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This effect of TNF- might be aggravated by the α
potentially vicious cycle of macrophage recruitment
to adipose tissue, which produces inflammatory
cytokines (including TNF- ). These cytokines α
result in further angiogenesis and adipogenesis in
morbid obesity. However, further study of these
interactions is necessary because TNF- also α
increased the expression of the OPG decoy
receptor.
Insulin and Rosiglitazone suppressed OPG in
differentiated 3T3L1 adipocytes (Fig. 4 and 5).
Similar results have been observed in human vas-
cular smooth muscle cells.
26 RANKL expression
was relatively preserved after treatment with in-
sulin or Rosiglitazone, suggesting that some of the
angiogenic effects induced by insulin or Rosigli-
tazone may be mediated through a decrease in the
OPG/RANKL ratio in adipose tissue.
Like most adipokines, however, secretion of
OPG into the media from both undifferentiated
and fully differentiated 3T3L1 cells was barely de-
tectable by ELISA. In order to exclude the pos-
sibility that the translation of OPG in adipocytes
was impaired, we transfected 3T3L1 cells with
OPG cDNA before and after differentiation.
Indeed, we were able to detect an elevation of
OPG in media, suggesting that the amount of
OPG secreted from differentiated 3T3L1 cells may
be below the detection limits of ELISA.
Our study was limited by the fact that the OPG
protein was only detected in OPG-transfected
cells. Accordingly, we were unable to draw con-
clusions about the physiologic role of OPG.
Further study of the functional significance of
OPG expression in adipocytes is needed.
In conclusion, we demonstrated that OPG ex-
pression was elevated during adipocyte differen-
tiation and after TNF- treatment in differentiated α
adipocytes. Considering the role of OPG in obe-
sity-associated inflammatory changes in adipose
tissue and vessels, we speculate that OPG plays
a protective role against inflammation and angio-
genic effects on adipose tissue. Although a causal
relationship between OPG and TNF-α in vivo has
not been established, we cautiously propose that
OPG might be one of the adipocytokines that can
reflect systemic inflammatory status. Further
study is needed to clarify this issue.
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